Marruecos-Querol J, Rubió-Casadevall J, Lozano A, Buxó M, Puigdemont M, Linares I, Planas I, Vayreda J, Cirauqui B, Taberna M, Quiroga V, Tobed M, Borés A, Recalde S, Saigi M, Felip E, Eraso A, Mesía R
Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R
SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
Rubió-Casadevall J, Ciurana E, Puigdemont M, Sanvisens A, Marruecos J, Miró J, Urban A, Palhua RL, Martín-Romero F, Ortiz-Duran MR, Marcos-Gragera R
Population-Based Analysis of Trends in Incidence and Survival of Human Papilloma Virus-Related Oropharyngeal Cancer in a Low-Burden Region of Southern Europe
Sant M, Magri MC, Maurichi A, Lillini R, Bento MJ, Ardanaz E, Guevara M, Innos K, Marcos-Gragera R, Rubio-Casadevall J, Sánchez Pérez MJ, Tumino R, Rugge M, Minicozzi P, The Melanoma Hr Study Working Group
Association of Sentinel Node Biopsy and Pathological Report Completeness with Survival Benefit for Cutaneous Melanoma and Factors Influencing Their Different Uses in European Populations
Hitt R, Mesía R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, Rubió-Casadevall J, Martínez-Trufero J, Morillo EDB, García Girón C, Vázquez Estévez S, Cirauqui B, Cruz-Hernández JJ
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J
Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis
Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, Rubió-Casadevall J, Plana Serrahima M, Ponce Ortega JM, Planas Toledano I, Caballero J, Marruecos Querol J, Iglesias Docampo L, Lambea Sorrosal J, Adansa JC, Mesía Nin R, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study
